See more : Sweden Buyersclub AB (BUY.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectar Biosciences, Inc. (CLRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectar Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hotel Shilla Co.,Ltd (008775.KS) Income Statement Analysis – Financial Results
- 49 North Resources Inc. (FNR.V) Income Statement Analysis – Financial Results
- Soaring Eagle Acquisition Corp. (SRNGW) Income Statement Analysis – Financial Results
- Shanghai Tianchen Co.,Ltd (600620.SS) Income Statement Analysis – Financial Results
- Biffa plc (BFFBF) Income Statement Analysis – Financial Results
Cellectar Biosciences, Inc. (CLRB)
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 4.96K |
| Cost of Revenue | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K |
| Gross Profit | -192.38K | -238.87K | -227.64K | -207.93K | -189.36K | -82.27K | -1.55M | -356.67K | -362.50K | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 2.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 48.85% |
| Research & Development | 27.27M | 19.22M | 17.59M | 10.14M | 9.00M | 6.84M | 9.47M | 4.75M | 5.16M | 5.96M | 6.86M | 5.12M | 3.60M | 3.00M | 8.08M | 14.53M | 17.43M | 6.44M | 1.14M | 261.77K |
| General & Administrative | 10.75M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 0.00 | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 0.00 | 0.00 |
| Selling & Marketing | 945.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.69M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 2.69M | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 1.44M | 365.88K |
| Other Expenses | 0.00 | 0.00 | 6.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 627.64K |
| Cost & Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 630.18K |
| Interest Income | 0.00 | 152.52K | 2.28K | 10.90K | 42.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 4.50K | 2.42K | 1.01K | 130.61K | 729.92K | 637.75K | 49.88K | 95.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.69K | 16.61K | 7.90K | 841.00 | 446.31K | 9.35K | 9.34K | 430.02K | 2.42K | 1.01K | 130.61K | 0.00 | 0.00 | 0.00 | 208.74K |
| Depreciation & Amortization | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 367.20K | 424.76K | 497.25K | 584.84K | 35.34K | 32.35K | 16.89K | 15.37K | 9.52K | 3.24K | 2.54K |
| EBITDA | -38.77M | -28.67M | -23.98M | -15.15M | -13.90M | -13.16M | -12.05M | -9.09M | -8.19M | -9.30M | -10.88M | -8.29M | -6.33M | -12.96M | -10.17M | -16.59M | -19.54M | -8.28M | -2.94M | -604.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45,388.96% | -38,876.20% | 2,049.87% | -13,164.56% | 0.00% | 0.00% | -16,968.75% | -12,172.63% |
| Operating Income | -38.96M | -28.81M | -24.13M | -15.29M | -14.18M | -13.33M | -13.60M | -9.45M | -8.76M | -9.89M | -12.40M | -8.75M | -7.04M | -5.45M | -10.17M | -16.59M | -20.29M | -8.93M | -5.09M | -625.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 63,979.27% | -16,351.72% | -10,555.25% | -13,170.82% | 0.00% | 0.00% | -40,428.32% | -12,600.14% |
| Total Other Income/Expenses | 917.15K | 152.52K | 8.92K | 196.18K | 85.71K | 91.74K | 38.68K | 3.27M | 3.26M | 1.78M | 522.76K | -42.19K | -1.89M | -7.20M | -12.11M | 139.61K | 737.05K | 382.63K | -487.02K | -190.07K |
| Income Before Tax | -38.04M | -28.66M | -24.12M | -15.09M | -14.09M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.75M | -12.65M | -26.28M | -22.96M | -29.72M | -8.55M | -3.16M | -815.29K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 70,469.15% | -37,960.15% | -27,289.52% | -18,227.50% | 0.00% | 0.00% | -25,146.86% | -16,430.57% |
| Income Tax Expense | -60.00K | -60.00K | -152.20K | -337.63K | -218.51K | -1.55M | -38.68K | -3.27M | -3.42M | -1.56M | -522.76K | 9.34K | 1.14M | -7.55M | 12.11M | -139.61K | -737.05K | -643.75K | 487.02K | 0.00 |
| Net Income | -37.98M | -28.60M | -23.97M | -14.76M | -13.87M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.44M | 2.10M | -22.27M | -16.45M | -19.56M | -8.29M | -3.05M | -815.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 67,594.75% | 6,286.05% | -23,125.72% | -13,059.99% | 0.00% | 0.00% | -24,264.14% | -16,430.57% |
| EPS | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| EPS Diluted | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| Weighted Avg Shares Out | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
| Weighted Avg Shares Out (Dil) | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2024 Earnings Conference Call November 18, 2024 8:30 AM ET Company Participants Anne Marie Fields - Managing Director, Precision AQ Jim Caruso - President & CEO Chad Kolean - CFO Andrei Shustov - SVP,...
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66 th Annual American Society of Hematology Meeting and Exposition
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programs
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report...
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced today it received a letter dated October 31, 2024, from Nasdaq, Inc. informing the Company that it had regained compliance...
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia
Jorge Castillo, M.D. to Present Iopofosine I 131 Activity in Bing-Neel Syndrome Andrei Shustov, M.D.
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the Company had received...
Source: https://incomestatements.info
Category: Stock Reports